British Heart Rhythm Society Clinical Practice Guidelines on the Management of Patients Developing QT Prolongation on Antipsychotic Medication-Reference-Cited by-同舟云学术

British Heart Rhythm Society Clinical Practice Guidelines on the Management of Patients Developing QT Prolongation on Antipsychotic Medication

Published:2019-08-09 Issue:3 Volume:8 Page:161-165
ISSN:2050-3369
Container-title:Arrhythmia & Electrophysiology Review
language:en
Short-container-title:Arrhythm Electrophysiol Rev

Author:

Lambiase Pier D¹,de Bono Joseph Paul²,Schilling Richard J³,Lowe Martin³,Turley Andrew⁴,Slade Alistair⁵,Collinson Jason⁶,Rajappan Kim⁷,Harris Stuart⁸,Collison Jason⁶,Carpenter Viki⁹,Daw Holly³,Hall Angela¹⁰,Roberts Eleri¹¹,Holding Shona¹²,Paisey John¹³,Sopher Mark¹⁴,Wright Ian¹⁵,Wiles Benedict¹⁶,Murgatroyd Francis¹⁷,Taylor David¹⁸

Affiliation:

1. UCL and Barts Heart Centre, London, UK

2. University Hospitals Birmingham, UK

3. Barts Heart Centre, London, UK

4. James Cook University Hospital, Middlesbrough, UK

5. Royal Cornwall Hospital, Truro, UK

6. Basildon Hospital, Essex, UK

7. John Radcliffe Hospital, Oxford, UK

8. Essex Heart Centre, UK

9. Addenbrooke’s Hospital, Cambridge, UK

10. Jersey General Hospital, Jersey

11. Manchester University NHS Foundation Trust, Manchester, UK

12. Westcliffe Medical Group Practice/Community Cardiology Service, Shipley, UK

13. University Hospital Southampton, UK

14. Royal Bournemouth Hospital, UK

15. Hammersmith Hospital, London, UK

16. Southampton General Hospital, Southampton, UK

17. King’s College Hospital, London, UK

18. King’s Health Partners, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

Abstract

The British Heart Rhythm Society’s Clinical Practice Guidelines on the Management of Patients Developing QT Prolongation on Antipsychotic Medication are written for heart rhythm consultants, primary care physicians, specialist registrars, nurses and physiologists who may be requested to review ECGs or advise on cases where antipsychotic-induced QT prolongation is suspected or proven. The guidance is adapted from the latest Maudsley Prescribing Guidelines in Psychiatry, published in 2018.

Publisher

Radcliffe Group Ltd

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference42 articles.

1. 1. Taylor DM, Barnes TRE, Young AH. Maudsley Prescribing Guidelines in Psychiatry. 13th edition. Chichester: Wiley Blackwell; 2018.

2. 2. Brown S. Excess mortality of schizophrenia. A meta-analysis. Brit J Psychiatry 1997;171:502-8.

3. 3. Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med 2005;118(Suppl 2):12S-22S.

4. Serious cardiovascular events and mortality among patients with schizophrenia;Enger;J Nerv Ment Dis,2004

5. Antipsychotic treatment and mortality in schizophrenia;Torniainen;Schizophr Bull,2015

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Updated Safety Review of the Relationship Between Atypical Antipsychotic Drugs, the QTc Interval and Torsades de Pointe As: Implications for Clinical Use;Expert Opinion on Drug Safety;2024-08-13

2. Antipsychotic-Induced QT Prolongation and Torsade de Pointes in Patients with Mental Disorders: A Review;Safety and Risk of Pharmacotherapy;2024-05-16

3. A real-world pharmacovigilance study of drug-induced QT interval prolongation: analysis of spontaneous reports submitted to FAERS;Frontiers in Cardiovascular Medicine;2024-05-13

4. KardiaMobile 6L for measuring QT interval in people having antipsychotic medication to inform early value assessment: a systematic review;HEALTH TECHNOL ASSES;2024

5. Assessment of Drug-Induced QTc Prolongation in Mental Health Practice: Validation of an Evidence-Based Algorithm;Risk Management and Healthcare Policy;2023-10